Distinguishing bone infection from soft-tissue infection in a diabetic foot ulcer is one of the more consequential diagnostic decisions in diabetic foot care. Diabetic foot osteomyelitis (DFO) changes the treatment calculus substantially: it typically requires longer courses of antibiotics, more frequently involves surgical debridement or bone resection, and carries a materially higher risk of amputation than soft-tissue infection alone. Yet no single bedside test or imaging study reliably confirms or excludes bone infection on its own, which is why diagnosis is best understood as a layered process combining clinical probing, imaging, and, when feasible, bone sampling.
Probe-to-Bone Testing as a First-Line Bedside Tool
The probe-to-bone (PTB) test, in which a sterile blunt probe is passed through an open ulcer to check for a hard, gritty structure consistent with cortical bone, remains the simplest and most widely used bedside screening maneuver. A systematic review and meta-analysis by Lam and colleagues, pooling seven studies, reported a sensitivity of 0.87 and specificity of 0.83 for the PTB test in detecting osteomyelitis. The authors concluded that the test performs best as a probability-adjusting tool rather than a stand-alone diagnostic: a positive result substantially raises the likelihood of bone infection in patients who already have a high pretest probability (for example, a large, deep, or chronic ulcer with exposed bone), while a negative result is more useful for ruling out osteomyelitis in lower-risk wounds. Its accuracy declines meaningfully in populations with a low prevalence of osteomyelitis, underscoring that clinical context should guide how heavily the result is weighted.
Imaging: Comparing MRI, Nuclear Medicine, and PET
When probing is equivocal or a more definitive noninvasive assessment is needed, imaging plays a central role. A systematic review and meta-analysis by Lauri and colleagues, published in Diabetes Care, pooled 29 studies evaluating magnetic resonance imaging (MRI), white blood cell (WBC) scintigraphy, and 18F-FDG-PET/CT. MRI demonstrated the highest sensitivity (93%) but comparatively lower specificity (75%), meaning it is excellent for excluding osteomyelitis but more prone to false positives, often driven by adjacent soft-tissue edema or Charcot changes that can mimic infection. In contrast, 99mTc-HMPAO-labeled WBC scintigraphy and 18F-FDG-PET/CT both achieved sensitivity around 89–91% with notably higher specificity (92%), making them useful for confirming infection when MRI findings are ambiguous or when hardware or Charcot deformity complicates MRI interpretation. The authors concluded that no single imaging modality is uniformly superior, and selection should account for availability, cost, radiation exposure, and the specific diagnostic question being asked.
Bone Biopsy: Strengths and Limitations of the Reference Standard
Bone culture and histology are generally regarded as the reference standard for confirming DFO and for guiding pathogen-directed antibiotic therapy. A systematic review and meta-analysis by Schechter and colleagues, examining percutaneous bone biopsy across 11 studies and more than 800 biopsies, found a pooled culture-positive yield of 84%, with higher positivity when biopsies were obtained through an open ulcer (96%) compared to intact skin (80%). Notably, the review found poor concordance between bone culture and superficial wound swab results, with identical organisms recovered in only 2.8% to 17.4% of paired samples, reinforcing that swab cultures are an unreliable surrogate for bone pathogens. Reported complication rates were low where documented, though the authors noted inconsistent reporting standards across studies, and one study linked biopsy-guided antibiotic selection to improved amputation-free survival compared with empiric therapy.
An Evidence-Based, Stepwise Approach
The 2023 IWGDF/IDSA guideline on diabetes-related foot infections, led by Senneville and colleagues, reinforced the safety of bedside percutaneous bone biopsy for suspected DFO and shortened the recommended post-treatment follow-up needed to confirm remission from 12 months to 6 months. The guideline also supports shorter antibiotic courses, including 10 days for moderate-to-severe soft-tissue infections following adequate surgical debridement, while emphasizing that osteomyelitis typically warrants a distinctly different, and generally longer, treatment approach once bone involvement is confirmed. Taken together, the literature supports a stepwise diagnostic pathway: clinical suspicion and probe-to-bone testing to establish pretest probability, targeted imaging (MRI as a first-line study in most cases, with nuclear imaging as an adjunct when specificity is paramount), and bone biopsy for culture and histology whenever the diagnosis remains uncertain or targeted antibiotic therapy is planned.
Clinical Summary
No single test reliably diagnoses diabetic foot osteomyelitis in isolation. Probe-to-bone testing is a useful, low-cost bedside adjunct that performs best in patients with a high pretest probability. MRI offers strong sensitivity for initial imaging, while WBC scintigraphy and FDG-PET/CT provide higher specificity when confirmation is needed. Bone biopsy remains the reference standard for both diagnosis and antibiotic selection, particularly given the poor correlation between wound swab and bone culture results. Combining these modalities within a structured, risk-stratified pathway, consistent with current IWGDF/IDSA guidance, offers the most reliable route to an accurate diagnosis and appropriately targeted treatment.
References
Lam K, van Asten SA, Nguyen T, La Fontaine J, Lavery LA. Diagnostic Accuracy of Probe to Bone to Detect Osteomyelitis in the Diabetic Foot: A Systematic Review. Clinical Infectious Diseases. 2016;63(7):944-948.
Lauri C, et al. Detection of Osteomyelitis in the Diabetic Foot by Imaging Techniques: A Systematic Review and Meta-analysis Comparing MRI, White Blood Cell Scintigraphy, and FDG-PET. Diabetes Care. 2017;40(8):1111-1120.
Schechter MC, et al. Percutaneous Bone Biopsy for Diabetic Foot Osteomyelitis: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases. 2020;7(10):ofaa393.
Senneville E, et al. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-Related Foot Infections (IWGDF/IDSA 2023). Clinical Infectious Diseases / Diabetes/Metabolism Research and Reviews. 2023-2024.
Comments
